Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Handok

Status and phase: Not yet enrolling; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: HD-P023; Drug: Empagliflozin; Drug: Teneligliptin

Study type: Interventional

Funder types: Industry

Identifiers

NCT06339788

HD-MP-106

Details and patient eligibility

About

The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

Enrollment: 40 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients who are 19 years or older on screening
• Signed informed consent
• Healthy Volunteer
• Other inclusion applies

Exclusion criteria

• Clinically relevant/significant findings as evaluated by the investigator
• Other exclusion applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

HD-P023

Experimental group

Description:

One tablet of HD-P023 by oral

Treatment:

Drug: HD-P023

Co-administration of Teneligliptin and Empagliflozin High

Active Comparator group

Description:

One tablet each of Teneligliptin and Empagliflozin High by oral

Treatment:

Drug: Teneligliptin

Drug: Empagliflozin